An interventional study of Renalive® LP, in CKD, Low Protein Dietary Intake and Malnutrition (Calorie), sponsored by Fresenius Kabi Taiwan Ltd.. Recruiting at 2 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Fresenius Kabi Taiwan Ltd. (part of Fresenius Kabi) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Malnutrition by Fresenius Kabi — 4 open to participants now, 4 under way, none of them phase 3. Malnutrition · Fresenius Kabi.
Among the 13 studies in Malnutrition by Fresenius Kabi, this one is one of 2 that started in 2025, is one of 4 with no phase, and was the 12th registered.
1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.
Browse Malnutrition studies →4 of the 13 studies in Malnutrition by Fresenius Kabi are open now, in 2 countries. Recruiting first, the newest first:
Fresenius Kabi Taiwan Ltd. · Sites in Taiwan
Ages 18+
Fresenius Kabi · Sites in United States
Ages 1 days–17 yrs
Fresenius Kabi · Sites in United States
Ages 1 mo–17 yrs
By country, each count listing its studies:
Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 80 is below the median of 119 across 844 interventional studies indexed under Malnutrition.
Median enrollment 20 across the 9 interventional studies, 315 across the 4 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Fresenius Kabi Taiwan Ltd., one of the names counted as Fresenius Kabi. Under that name alone:
Fresenius Kabi Taiwan Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
1 of the studies in Malnutrition by Fresenius Kabi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06049680Fresenius KabiSafety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Malnutrition by Fresenius Kabi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Inclusion criteria (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\<45 mL/min/1.73 m2)
Exclusion criteria
(1) Has received dialysis or are expected to start dialysis within the next 3 months.
The criteria were revised on the registry on Sep 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(1) Diagnosed with chronic kidney disease stage 3b-5 (with history of \<45 mL/min/1.73 m2)
Exclusion Criteria:
(1) Has received dialysis or are expected to start dialysis within the next 3 months
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Renalive® LP,
flavour
Change in body weight from Baseline to end of treatment at Week 4 (Week 4 - Baseline)
Time frame: 4 weeks
Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.
Of 419 interventional studies with no phase under Malnutrition, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 30 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Apr 2026 → Dec 2027 and completion Apr 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.